Skip to main content

Clinical trial SYD985.004

A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours

Cancers
Organ Tumeurs solides
Trial status Trial open for recruitment
Investigator
Trial type
Interventionnal with IMP
Phase Trial phase 1
Academic trial Non
Sponsor Synthon Biopharmaceuticals
EudraCT Identifier 2019-002937-12
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04235101
Inclusion criteria RECIST v1.1
Last update